Hyperphosphatemia and
dyslipidemia are common clinically significant conditions in
end-stage renal disease (
ESRD).
Hyperphosphatemia management is essential; however, use of
calcium-based
phosphate binder has been associated with elevated risk of cardiac calcification in
ESRD, increasing risks for
cardiovascular disease and death. An alternative to
calcium-based
phosphate binders is
sevelamer hydrochloride, a
calcium-free,
metal-free, nonabsorbed
polymer that binds
phosphate effectively. We conducted a meta-analysis on the effects of
sevelamer hydrochloride on parameters of
mineral metabolism (serum phosphorous,
calcium, Ca x P, and iPTH) and the
lipid profile (total,
LDL, HDL, and non-
HDL cholesterol, and
triglycerides) in dialysis patients. After application of inclusion/exclusion criteria, 17 core studies were statistically analyzed to determine the
sevelamer treatment effect on the study parameters as demonstrated by simple, n-weighted, and inverse variance-weighted mean changes. Analysis of inverse variance-weighted mean changes indicated that
sevelamer treatment was associated with a 2.14 mg/dL drop in serum
phosphorus (P <.001), no significant overall effect on
calcium (0.09 mg/dL, P =.364), significant decline in Ca x P product (15.91 mg(2)/dL(2), P <.001), 35.99 pg/mL reduction in iPTH (P =.026), significant reduction in total
cholesterol (30.58 mg/dL, P <.001), 31.38 mg/dL drop in
LDL cholesterol (P <.001), significant increase in
HDL cholesterol (4.09 mg/dL, P =.008), and a significant reduction in
triglycerides (22.04 mg/dL, P x.001). This meta-analysis suggests that
sevelamer offers a dual therapeutic benefit in dialysis patients-a population at high risk for
cardiovascular disease-by improving
phosphorus control and the
lipid profile, without altering serum
calcium.